Source comparison
MOTS-c Dosage Metabolism 2026: Comparison of Protocols
5mg twice weekly (Mon/Thu) 10mg Sustained peaks every 3–4 days 22–31% reduction at 12 weeks Minimal. Occasional injection site redness Gold standard for metabolic research in 2026; best risk-to-benefit ratio 10mg once weekly Single peak, returns to baseline by
This comparison does not assign a generated winner or score.
- 5mg twice weekly (Mon/Thu)
- 10mg
- Sustained peaks every 3–4 days
- 22–31% reduction at 12 weeks
- Minimal. Occasional injection site redness
- Gold standard for metabolic research in 2026; best risk-to-benefit ratio
- 10mg once weekly
- Single peak, returns to baseline by day 5
- 12–18% reduction at 12 weeks
- Low. Similar to 5mg twice weekly
- Suboptimal due to prolonged trough periods; inconsistent AMPK signalling
- 10mg twice weekly (Mon/Thu)
- 20mg
- High sustained activation
- 28–35% reduction at 12 weeks
- Moderate. Injection site reactions, transient fatigue in 15–20% of subjects
- Effective but higher side effect incidence; reserve for research contexts with close monitoring
- 15mg twice weekly
- 30mg
- Very high activation, potential receptor saturation
- 30–38% reduction at 12 weeks
- Moderate to high. Fatigue, headache, increased renal clearance markers
- Not recommended outside controlled research; no additional benefit over 10mg twice weekly
- Daily microdosing (2mg/day)
- 14mg
- Continuous low-level activation
- 15–22% reduction at 12 weeks
- Very low. Almost no injection site reactions
- Emerging protocol in 2026 research; promising for long-term use but requires daily compliance